|
Dr. Daley received his M.D. degree from the University of Mississippi
in 1983. He was a resident in Internal Medicine, chief resident,
and pulmonary and critical care fellow at the University of California,
San Francisco. In 1991, he joined the faculty at San Francisco
General Hospital where he is Chief of the Pulmonary Clinic and
Medical Director of the TB Training Center at the F. J. Curry
National Tuberculosis Center. Dr. Daley is past-president of the
California Tuberculosis Controllers Association and president-elect
of the California Thoracic Society. His major academic interests
include medical education and clinical and epidemiologic research
with tuberculosis and nontuberculous mycobacteria.
Tuberculosis continues to plague much of
the world, killing more adults than any other infectious disease.
The parallel pandemic of HIV infection has contributed to a resurgence
of tuberculosis in many areas of the world. Moreover, in some
areas, levels of multidrug resistant tuberculosis have reached
alarming levels. A recent report by the Institute of Medicine
has called for the development and evaluation of new diagnostic
tests for latent tuberculosis infection and active disease as
well as the development of new antituberculosis drugs, treatment
regimens, and vaccines. Dr. Daley and his colleagues are actively
involved in such studies of new diagnostic tests and treatment
regimens.
Since 1999, Dr. Daley has been the San
Francisco site director of a multicenter Tuberculosis Trials Consortium
(TBTC) funded by the Centers for Disease Control and Prevention.
This consortium is currently involved in several clinical trials
of new regimens, pharmacokinetic studies of antiretroviral agents
and rifabutin, and a new rifapentine-based regimen for treatment
of latent infection. Dr. Daley, along with Dr. Phil Hopewell and
Dr. Chip Chambers (Chief of Infectious Diseases at SFGH), are
also part of the NIH-funded Tuberculosis Research Unit (TBRU).
Their role in this multicenter research group is to coordinate
domestic Phase I and II clinical trials with new drugs and vaccine
candidates.
Dr. Daley has coordinated the study
of the molecular epidemiology of tuberculosis with Phil Hopewell
and Peter Small (Stanford) since 1993. By utilizing genotyping
techniques, the group has written extensively about the transmission
and pathogenesis of tuberculosis in San Francisco. The research
group has now genotyped over 2000 strains of Mycobacterium
tuberculosis and has a large dataset that is available for
analysis.
Dr. Daley was a recipient of a Tuberculosis
Academic Award, funded by the National Heart, Lung, and Blood
Insititute. The award was used to develop a curriculum in tuberculosis
education at UCSF. In this regard, Dr. Daley developed an integrated
curriculum and a large number of standardized test questions.
As Medical Director of the CDC-funded TB Training Center at the
F. J. Curry National TB Center, he has helped to develop a number
of innovative education and training materials, including satellite
courses, audiotapes, videotapes, CD-ROMs, and internet-based CME
courses.
Dr. Daley coordinates a training program
in International Tuberculosis Control that is funded by the Fogarty
Foundation. This program, which is under the direction of Lee
Riley at UC Berkeley, allows interested individuals from other
countries to come to UCSF (and UCB) for 1-2 years for course work,
clinical training, and research.
Daley CL, Mugusi F, Chen L, et al. Pulmonary
complications of HIV infection in Tanzania: role of bronchoscopy
and bronchoalveolar lavage. Am J Respir Crit Care Med 1996;154:105-110.
Daley CL, Hahn JA, Moss A, Hopewell PC,
Schecter GF. Incidence of tuberculosis in injection drug users
in San Francisco. Am J Respir Crit Care Med 1998;157:19-22.
Chin DP, De Riemer K, Small PM, Ponce de
Leon A, Steinhart R, Schecter GF, Daley CL, Moss Ar, Paz A, Jasmer
RM, Agasino CB, Hopewell PC. Interaction of factors contributing
to the incidence of tuberculosis in San Francisco. Am J Respir
Crit Care Med 1998;158:1797-1803.
DeRiemer K, Schecter GF, Hopewell PC, Daley
CL. Epidemiology of tuberculosis diagnosed at death in San Francisco.
Internat J Tuberc Lung Dis 1999;3:488-493.
Yeh RW, Hopewell PC, Daley CL. Simultaneous
infection with two strains of M. tuberculosis identified
by restriction fragment length polymorphism analysis. Internat
J Tuberc Lung Dis 1999;3:537-539.
Behr MA, Warren SA, Ponce de Leon A, Salamon
H, Daley CL, Hopewell PC, Small PM. Infectivity of AFB smear-negative
tuberculosis patients in San Francisco. Lancet 1997:53;444-449.
Jasmer RM, Hahn J, Small PM, Daley CL,et
al. A molecular epidemiologic analysis of tuberculosis trends
in San Francisco, 1991-1997. Ann Intern Med 1999;130:971-978.
Jasmer RM, Snyder DC, Chin DP, Cuthbert
SS, Paz EA, Hopewell PC, Daley CL. Twelve months of isoniazid
compared to four months of isoniazid and rifampin for persons
with radiographic evidence of previous tuberculosis: an outcome
and cost effectiveness analysis. Am J Respir Crit Care
Med 2000;162:1648-1652.
Conde MB, Soares SLM, Mello FQ, Rezende
VM, Almeida LL, Reingold A, Daley CL, Kritski AL. Prospective
comparison of sputum induction with fiberoptic bronchoscopy in
the diagnosis of tuberculosis. Experience at an AIDS reference
center in Rio de Janeiro, Brazil. Am J Respir Crit Care Med
2000;162:2238-2240.
Ziv E, Daley CL, Blower S. Early therapy
for latent infection. Am J Epidemiol 2001;4:381-385.
|
